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ABSTRACT 
               Wolfram syndrome is a genetic disorder characterized by diabetes and 
neurodegeneration. Two causative genes have been identified so far, WFS1 and WFS2, 
both encoding endoplasmic reticulum (ER) localized transmembrane proteins. Since 
WFS1 is involved in the ER stress pathway, Wolfram syndrome is considered an ER 
disease. Despite the underlying importance of ER dysfunction in Wolfram syndrome, the 
molecular mechanism linking ER to the death of β cells and neurons has not been 
elucidated. 
               The endoplasmic reticulum (ER) is an organelle that forms a network of 
enclosed sacs and tubes that connect the nuclear membrane and other organelles 
including Golgi and mitochondria. ER plays critical functions in protein folding, protein 
transport, lipid metabolism, and calcium regulation. Dysregulation of ER function 
disrupts normal cell metabolism and activates an array of anti-survival pathways, 
eventually leading to disease state. 
               Here we show that calpain is involved in both prototypes of Wolfram syndrome. 
Calpain 2 activity is negatively regulated by WFS2 protein, and hyper-activation of 
calpain 2 by WFS2-knockdown leads to cell death. Calpain hyper-activation is also 
present in WFS1 loss of function cells due to the high cytosolic calcium. Extensive 
calpain activation exists in the Wolfram syndrome mouse model as well as in patient cells. 
A compound screen targeting ER homeostasis reveals that dantrolene, a ryanodine 
receptor inhibitor, can prevent cell death in cell models of Wolfram syndrome. Our 
vi 
results demonstrate that the pathway leading to calpain activation provides potential 
therapeutic targets for Wolfram syndrome and other ER diseases. 
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CHAPTER I 
INTRODUCTION 
 
1.1 Diabetes and Wolfram syndrome 
               Diabetes mellitus is a metabolic disease affecting 382 million people worldwide 
and 28.6 million people in the United States. Each year, 1.5 to 5.1 million deaths are 
cause by diabetes mellitus worldwide, making it the 8th leading cause of death (World 
Health Organization, 2014). Diabetes is a group of diseases featured by patients 
experiencing abnormally high level of glucose over a prolonged period of time. In 
healthy population, glucose is generated after food absorption or breakdown of glycogen 
and other non-carbohydrate storage and is quickly uptaken by tissues such as liver, 
adipose tissue and muscles under the regulation of insulin.  However, diabetic patients 
have defect in glucose uptake, resulting in elevated blood glucose level, a status called 
hyperglycemia. Symptoms of diabetes include excessive thirst, hunger, frequent urination, 
and weight loss. If left untreated, other complications may occur, such as eye problems, 
kidney failure, leg and foot pain, weakened immune system and nerve damage (Amos, 
1997; Bell & Polonsky, 2001). 
               Insulin is a hormone release by pancreatic β cells, which are located at the islets 
of Langerhans in the pancreas. It ensures the blood glucose level homeostasis through 
binding to the cell surface insulin receptors and stimulating uptake of blood glucose into 
tissue cells. From there, glucose will be either consumed as an energy source or 
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converted for storage. In incidence of insulin production impairment or insulin resistance 
(inefficient cellular response to insulin), excess glucose cannot be absorbed (Muoio & 
Newgard, 2008). If blood glucose level is constantly high, many diabetic complications 
will occur. On the other hand, when blood glucose drops, insulin secretion decreases and 
secretion of another hormone by the pancreatic alpha cells—glucagon will be released 
leading to the inhibition of glucose absorption and breakdown of glycogen to increase 
blood glucose levels.  
1.1.1 Major types of diabetes 
               There are two major forms of diabetes, Type 1 diabetes and Type 2 diabetes. 
               Type 1 diabetes (Diabetes mellitus type 1 or T1D) accounts for five to ten 
percent of all diabetic patients. It is an autoimmune disease in which pancreatic β cells 
are attacked and eliminated (Bluestone et al, 2010). Due to the importance of insulin in 
glucose transport and metabolism, T1D patients have elevated blood and urine glucose 
levels. Necessary treatment for the disease is insulin injection. 
               Type 2 diabetes (Diabetes mellitus type 2 or T2D) usually occurs among adults. 
About 90 percent of diabetic patients are T2D. Symptoms include hyperglycemia, insulin 
resistance and partial loss of pancreatic β cells. The cause of the disease is more 
complicated than T1D, it is a combination of genetics and environmental factors. The top 
risk factor for T2D is obesity, followed by diet, pregnancy, aging and gender (Kahn, 
1998). Unlike T1D, T2D patient still have residual pancreatic βeta cells that can secrete 
insulin. These cells are usually overwhelmed by excessive demand of insulin production 
3 
due to the high blood glucose level, leading to cellular stress and eventually reduction of 
β cell mass. T2D patients also develop insulin resistance, in which case, glucose uptake 
by corresponding tissues is not sensitive to insulin regulation.  A major concern in the 
field is how to improve the insulin sensitivity in T2D. 
1.1.2 Wolfram syndrome  
               Wolfram syndrome is a rare autosomal recessive disease characterized by 
diabetes mellitus and optic atrophy usually during childhood or early adulthood. The 
prevalence of Wolfram is 1 in 770,000, with a carrier frequency of 1 in 354. It is also 
called DIDMOAD disease (Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy and 
Deafness) (Barrett et al, 1995). Diabetes is the first manifestation of Wolfram syndrome, 
occurring around age 6, followed by optic atrophy around age 11. Patients may also 
develop diabetes insipidus and deafness. Life expectancy of Wolfram syndrome is 30-40 
years. Neurological disorders appear in most of the patients, usually starting from 
adulthood, symptoms include ataxia and depression. Magnetic resonance imaging (MRI) 
showed that patients have thinning of brain stem and atrophy in the cerebellum, which 
gives explanation for the neural disorder seen in patients. (Figure 1.1) There are two 
genetics forms of Wolfram syndrome, Wolfram syndrome 1 and Wolfram syndrome 2. 
Wolfram syndrome 1 composes more than 90 percent of all Wolfram syndrome cases. 
               Wolfram syndrome 1 patients have mutations in the WFS1 gene, which encodes 
a protein called wolframin.  Wolframin is a 100 KDa protein with 9 transmembrane 
segments located at the endoplasmic reticulum (ER). Despite being ubiquitously 
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expressed, WFS1 level is especially high in pancreas and brain. Previously WFS1 has 
been well characterized in pancreatic β cells, showing it to be important for ER stress 
response. Pancreatic β cells with mutation in WFS1 gene have chronic high basal 
unfolded protein response (UPR) levels; they cannot recruit E3 ubiquitin ligase—HRD1 
to degrade activated ATF6 protein, leading to intolerable ER stress (Fonseca et al, 2010). 
WFS1 deficient cells also have impairment in insulin synthesis and are vulnerable to ER 
stress inducers. We used mice that have WFS1 specifically knocked out in pancreatic β 
cell (Ishihara et al, 2004; Riggs et al, 2005). These mice showed high UPR marker 
expression and defect in insulin production. However, these animals only developed 
impaired glucose stimulated insulin secretion and a reduction in β cell mass, but not 
insulin resistance. WFS1 has also been shown to be involved in calcium regulation, 
studies showed the critical role of WFS1 in retention of ER calcium level (Osman et al, 
2003). Some studies even proposed WFS1 as a new calcium channel. So far, over 100 
different mutations have been found in the WFS1 gene among Wolfram syndrome 
patients, including missense, nonsense and deletion mutations. These mutations 
concentrate mainly at transmembrane domains, N-terminal and the C-terminal of the 
protein. (Figure 1.2) It is also interesting to notice that 8.31% of Wolfram syndrome 
patients have only one WFS1 mutant allele (de Heredia et al, 2013). Therefore, in some 
cases of Wolfram syndrome, WFS1 mutants are autosomal dominant (Hansen et al, 2005). 
               Wolfram syndrome 2 patients have mutations in the WFS2 gene. WFS2 (also 
known as CISD2, Miner1, NAF-1 and Eris) is a not as well characterized as WFS1. It 
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Figure 1.1 Clinical characteristics of Wolfram syndrome patients. Adapted from Barrett and 
colleagues. The peak of each curve represents the median age of onset of the complications and 
the intersections with the x-axis represent the ranges. The dotted line corresponds to the median 
age of onset of neurologic complications in the Barrett’s series. D = deafness; DI = diabetes 
insipidus; DM = diabetes mellitus; Neuro = neurologic complications; OA = optic atrophy; R = 
renal tract abnormalities (Chaussenot et al, 2011). 
 
belongs to a protein family containing CDGSH iron-sulfur domain, another member of 
the family is mitoNEET, which has been identified as a target of the anti-diabetic drug—
Pioglitazone (Paddock et al, 2007). Patients with homozygous WFS2 mutation were first 
identified in three consanguineous Jordanian families with Wolfram syndrome (Amr et al, 
2007a). So far, 2 types of mutations in the WFS2 gene were discovered in Wolfram 
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syndrome patients. One is a point mutation in exon 2, the other type is a intragenic 
deletion in exon 2 (Mazzillo et al, 2014). Compared to patients with WFS1 mutations, 
WFS2 patients also develop diabetes and neuronal disorders. In addition, they exhibit 
clinical features such as bleeding tendency, defective platelet aggregation and peptic-
ulcer disease. Recently, WFS2 whole body knockout mice were generated. WFS2 
knockout mice exhibit shorter life span, glucose intolerance, neuron degeneration and 
muscle atrophy, whereas WFS2 knockin mice have longer lifespan compared to 
littermate controls (Chen et al, 2009b, 2009a). It has also been shown that WFS2 is 
involved in Belkin 1-dependent autophagy by binding ER BCL2 protein (Chang et al, 
2010). WFS2 patients compose less than 10 percent of Wolfram syndrome population, 
due to the rareness of Wolfram syndrome 2, there is no patient study thus far. Therefore, 
understanding the molecular function of WFS2 may help establish a treatment for 
Wolfram syndrome and related common diseases. However, very little is known about 
the WFS2 protein.  
               There is currently no treatment for Wolfram syndrome. Many Wolfram 
syndrome patients are treated as diabetic patients and this helps maintain their blood 
glucose levels. However, other complications cannot be controlled, such as neural 
complications. Central apnea is the major cause of death in Wolfram syndrome. It has 
been shown that neurologic complications occurred in over 50% of the patients with a 
median age of 15 (Chaussenot et al, 2011). The top 3 neurologic complications in 
Wolfram syndrome are cerebellar ataxia, peripheral neuropathy and cognitive impairment. 
These features suggest that there are neurodegeneration and neurodevelopmental 
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abnormalities in the patients, which is confirmed by MRI study of the human brain. MRI 
revealed atrophy in cerebellum, brain stem and cerebral in the majority of the patients, 
while optic atrophy, thinning of hypothalamus and infundibulum, abnormality of white 
matter, cortical abnormalities were also noticed in some patients (Hardy et al, 1999; 
Chaussenot et al, 2011). Due to the neuronal pathological features of the disease, 
understanding the cause of neuronal cell death in Wolfram syndrome became an urgent 
demand in the field. 
1.2 ER homeostasis 
               Endoplasmic reticulum is an organelle in eukaryotic cells that forms a network 
connecting the nuclear membrane and other organelles such as Golgi and mitochondria. It 
appears as membrane folded into enclosed sacs or tubes. There are two kinds of ER, 
rough endoplasmic reticulum (RER) and smooth endoplasmic reticulum (SER). The 
rough ER gets its name because of the ribosomes scattered on its cytosolic face while 
smooth ER does not have ribosomes binding to it. Endoplasmic reticulum functions in 
protein folding, protein transport, lipid metabolism, and calcium regulation (Figure 1.3) 
(Burdakov et al, 2005; Hebert & Molinari, 2007; Fu et al, 2012). The environment of the 
ER is very special compared to other cellular compartments. It has a high calcium 
concentration (about 10,000 fold higher calcium in the ER compared to cytosol), which 
makes it the ideal location for calcium dependent proteins (Clapham, 2007). The high 
calcium level in the ER can also function as a part of signal cascades operated by 
secondary messengers. What’s more, the ER lumen has an oxidative environment, which 
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is important for disulfide bond formation and proper protein folding. In addition, ER is 
the major location for protein modification. This is especially critical for secretory 
proteins, which need to be tagged before transported to the right locations. 
 
Figure 1.2 Disease mutations in WFS1 protein. WFS1 is an ER transmembrane protein. 
Mutations in WFS1 gene includes missense, nonsense and deletion mutations. There is no special 
hot spot where mutations occur (Reproduced from Farhat Khanim,1 Jeremy Kirk,2 Farida Latif,1 
and Timothy G. Barrett 2001). 
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precise signaling network to regulate the folding process called the unfolded protein 
response (UPR) (Ron & Walter, 2007; Kaufman et al, 2002). 
               Maintaining a balance between ER protein load and its folding capacity is 
critical for cell survival. However under certain circumstances, ER protein load exceeds 
its folding capacity, this will cause accumulation of unfolded/misfolded proteins in the 
ER, leading to ER stress. Eukaryotes developed a conserved pathway to counterbalance 
ER stress called the unfolded protein response. Under normal conditions, the UPR 
pathway ameliorates ER stress by suppressing global protein translation, accelerating the 
protein-folding process, and facilitating protein degradation. However, if the ER stress 
level is irreversible, the UPR will activate a different set of genes promoting cell death 
(Oslowski & Urano, 2011). Under ER stress conditions, the unfolded/misfolded proteins 
interact with ER localized chaperone—immunoglobin binding protein (BIP), releasing it 
from ER stress sensors, thus activating downstream signaling pathways. There are three 
ER stress sensors in the unfolded protein response pathway, IRE1, PERK and ATF6 
(Figure 1.4). 
               IRE1 (inositol-requiring enzyme 1) is a serine/threonine kinase with 
endoribonuclease activity (Mori et al, 1993). It is an ER transmembrane protein 
conserved in all eukaryotes (Tirasophon et al, 1998). Upon activation, IRE1 alternatively 
splices XBP1 mRNA, removing a 26nt intron, resulting in the production of XBP1s 
(Yoshida et al, 1998, 2001). XBP1s would then regulate downstream UPR signaling 
including genes involved in the ER associated degradation (ERAD) process (Lee et al, 
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2003). Recently IRE1 was found to cleave many other mRNA transcripts in the ER in 
addition to XBP1. Degradation of these mRNA can reduce the translation load, which is 
beneficial for stress recovery (Han et al, 2009; Hollien & Weissman, 2006). When ER 
stress is irreversible, IRE1 would activate pro-apoptotic signal cascade such as the JNK 
signaling pathway (Urano, 2000). 
               PERK (PKR-like ER kinase) functions as an ER transmembrane protein kinase 
of the PEK family (Harding et al, 1999). Under ER stress condition, PERK activation 
induces phosphorylation of eIF2α (Kimball, 1999). This shuts down global protein 
translation, which helps reduce the protein load in the ER. At the same time, eIF2α 
phosphorylation activates transcription factor ATF4, which can increase production of 
molecular chaperones and enhance amino acid metabolism, therefore ameliorates the 
accumulation of unfolded proteins (Vattem & Wek, 2004). However, prolonged 
suppression of protein synthesis is fatal for cells. Thus, if ER homeostasis cannot be 
achieved, programed cell death pathways will be activated. 
 ATF6 (activating transcription factor 6) is another transcription factor that can 
sense ER stress (Yoshida et al, 1998). It is tethered to the ER by BiP protein (Shen et al, 
2002). When ER stress occurs, BiP is released and ATF6 translocates to the Golgi where 
it is cleaved by proteases (S1P and S2P) into the processed form (Haze et al, 1999). Then, 
the processed ATF6 migrates into the nucleus and facilitates the transcription of 
downstream UPR genes. Targets of ATF6 include pro-survival genes involved in protein 
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1.2.2 Lipid metabolism and ER homeostasis 
               Lipid is mainly synthesized in the smooth endoplasmic reticulum. Because of 
the hydrophobic nature of lipids, they are synthesized in association with ER membrane. 
They are then transported to different parts of the cell. Certain cell types such as 
hepatocytes contain abundant smooth ER to adapt to the high demand of detoxification, 
removal of hydrophobic components, lipids processing and synthesis. 
               The ER is a membrane rich organelle where lipid composition can affect its 
membrane structure and membrane protein function (Fu et al, 2012). Treatment of cells 
with saturated fatty acid or cholesterol can induce acute ER stress which could be 
compensated by the UPR pathway (Borradaile et al, 2006; Wei et al, 2006; Feng et al, 
2003). Chronic lipid overload is even more pathological. For example, in some obese 
patients, lipid overload causes lipotoxicity and perturbed ER lipid composition, leading to 
functional impairment of SERCA, a main calcium pump at the ER. Therefore, ER 
homeostasis will be disrupted. (Li et al, 2004; Fu et al, 2011) 
1.2.3 Calcium regulation and ER homeostasis 
               Calcium is an important signaling molecule involved in all aspects of cellular 
functions including proliferation, trafficking, secretion, and apoptosis. Calcium is stored 
in the ER and mitochondria, and maintained at low concentration in the cytosol (10-100 
nM) by calcium pumps that actively pump calcium from the cytosol into the ER (Figure 
1.5). The most active calcium pump located at the ER is sarco/endoplasmic reticulum 
calcium-ATPase (SERCA), and SERCA pumps calcium into the ER at the cost of ATP 
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(Moore et al, 1975). The ER also contains several calcium channels that release calcium 
into the cytosol, including inositol 1,4,5-trisphosphate receptor (IP3R) and ryanodine 
receptor (RYR). It is critical to maintain high calcium concentration in the ER since 
many enzymes including molecular chaperones require calcium for proper function 
(Michalak et al, 2002). Additionally, low cytosolic calcium is also important to keep 
calcium mediated signaling events inactivate under normal circumstances (Berridge et al, 
2003). So once calcium is released into the cytosol, the large gradient wave of calcium 
can trigger a wide variety of signaling cascades.  
               SERCA (sarco/endoplasmic reticulum calcium-ATPase) is a calcium pump 
located at the ER. There are three genes encoding SERCA, ATPA1-3, whereby, 
transcription of the gene results in multiple splicing variants. The major form of ER 
calcium –ATPase in non-muscle tissue is SERCA2b. Inhibition of SERCA pump by 
thapsigargin activates the UPR pathway and induces ER stress. 
               IP3R (inositol 1, 4, 5-trisphosphate receptor) functions as a ubiquitously 
expressed calcium release channel located at the ER membrane. Binding of inositol 
trisphosphate (IP3) at the amino terminus of IP3R stimulates structural transition and 
channel opening at the carboxyl terminus. IP3R has various functions including cell 
proliferation, differentiation, and apoptosis. 
               RyR (ryanodine receptor) is a major calcium release channel at the ER 
membrane. Mammalian RyR exists in three different isoforms: RyR1 is mainly expressed 
in skeletal muscles; RyR2 is primarily expressed in the myocardium; RyR3 is expressed 
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Leakage of ER calcium into the cytosol raises the cytosolic calcium level, which would 
trigger the mitochondria to work as a calcium buffering system and uptake excess 
calcium. Normally, calcium is an important modulator in mitochondria acting as a stimuli 
for ATP synthesis. However, mitochondria calcium overload can enhance ROS 
generation, increase permeability of transition pores and trigger cytochrome c release 
leading to apoptosis (Brookes et al, 2004). High cytosolic calcium could also activate 
anti-survival calcium dependent proteases such as calpains. Once activated, these 
enzymes cleave a vast variety of substrates, damaging cellular structure and function 
(Zatz & Starling, 2005; Huang & Wang, 2001). 
1.2.4 ER homeostasis and disease 
1.2.4.1 UPR and diseases 
               In T1D, it was proposed that β cell death is induced by overproduction of NO, 
and the pro-apoptotic molecule--NO is regulated by CHOP, an ER stress pro-apoptotic 
transcription factor. In a genetic type of diabetic mouse model (Oyadomari et al, 2001), 
Akita mice have a high ER stress level. What’s more, homozygous deletion of CHOP 
significantly delays the disease onset (Oyadomari et al, 2002). In T2D mouse models, 
when the mice were fed with high fat diet, signs of ER stress have been found in islets, 
liver and adipose tissue (Ozcan et al, 2004). Ablation of CHOP can protect against 
apoptosis and preserve β cell mass (Oyadomari et al, 2002; Song et al, 2008). In addition, 
molecular chaperons such as PBA, TUDCA and curcumin have been proven to improve 
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protein-folding capacity and ameliorate ER stress, thus improving β cell survival, insulin 
sensitivity and glucose homeostasis in diabetic mice (Ozcan et al, 2006). 
               WFS1, the causative gene for Wolfram syndrome, is part of the UPR pathway. 
In a diabetic mouse model of Wolfram syndrome, E3 ligase HRD1 mislocalization leads 
to ATP6 hyper-activation in pancreatic β cells. This eventually causes the loss of β cell 
mass and impairment of insulin production. 
               Another typical ER stress disease is Wolcott-Rallison syndrome (WRS). It is a 
rare, autosomal recessive disorder with infancy-onset diabetes, multiple epiphyseal 
dysplasia, osteopenia, mental retardation or developmental delay, and hepatic and renal 
dysfunction as main clinical findings. Patients with WRS have mutations in the EIF2AK3 
gene, which encodes the PERK protein (Delépine et al, 2000). This blocks the 
phosphorylation of eIF2α, which will further prevent β cell development and induces cell 
death. 
                In the case of Alzheimer’s, PERK –eIF2α pathway is hyperactive in brain 
tissue, implying a relationship between ER stress and Alzheimer’s disease (Unterberger 
et al, 2006). Mutations in the Parkin protein account for a small portion of Parkinson’s 
disease. It is an E3 ubiquitin ligase and mutation of Parkin disrupts the ERAD system. In 
contrast, cells overexpressing Parkin are more resistant to ER stress induced cell death
(Dawson & Dawson, 2003). Two percent of ALS cases have a mutation in the SOD1 
gene. Mutant SOD1 protein forms aggregates that induce the UPR pathway through 
exhausting the proteasome activity in a failed attempt to degrade them. Moreover, SOD1 
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mutants could also directly bind the ERAD machinery, tipping the balance between 
protein production and degradation (Nishitoh et al, 2008). In another neurodegenerative 
disease, the prion disease, pathological form of the prion protein PrPsc can induce calcium 
depletion in the ER upon treatment, which results in the activation of the UPR. Molecular 
chaperones have been reported to be elevated in brains of these patients. This could be 
confirmed in cell culture that prion treated cells showed induction of ER stress markers 
(Hetz et al, 2005). A treatment strategy for prion disease is modulating ER stress levels 
by augmenting the expression of protein chaperones. 
                Reports show that proteins associated with the UPR are upregulated in rapidly 
growing tumors. These upregulated genes provide a protective effect in cancer cells 
(Shuda et al, 2003; Jamora et al, 1996; Bi et al, 2005). It is important we determine a way 
to inhibit the protective branches and activate the anti-survival branches of UPR in cancer 
cells for treatment purposes. Supporting this concept, chemical inhibitors of BiP are 
being investigated as a potential cancer drug target (Lee, 2007). At the same time, protein 
synthesis and modification is more active in cancer cells requiring massive protein 
regulatory machineries. Thus, by inhibiting protein regulation pathways such as the 
ERAD, anti-survival branches of the UPR could be activated. Proteasome inhibitors that 
can induce ER stress and promote cytotoxic effect in cancer cells are being studied for 
clinical purposes. Bortezomib, a proteasome inhibitor has been used as a treatment for 
multiple myeloma (Nawrocki et al, 2005). 
1.2.4.2 ER redox disease 
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               The endoplasmic reticulum has an irreplaceable role in protein folding and 
trafficking, which is extremely sensitive to ER luminal environment. Subtle changes in 
the redox state could impair ER function tremendously. Alterations of the components of 
ER redox system can cause redox change, including hypoxia, impairment in oxidative 
protein folding, deletion of glutathione (GSH), and decreased activity of folding 
machinery component PDI and production of ROS (Holtz et al, 2006; Bass et al, 2004; 
Uehara et al, 2006). Reactive oxygen species (ROS) production is a natural part of cell 
metabolism. However, if not removed properly, accumulation of ROS could be harmful 
for the cells. ROS production occurs in the cytosol and many other organelles including 
ER. Accumulation of ROS in the ER can lead to ER stress, which in turn could induce 
even more ROS production (Haynes et al, 2004). Diseases associated with redox change 
have been reported over the last few decades. In Parkinson’s disease, S-nitrosylation of 
PDI and parkin imply ROS presence in ER lumen of neurons (Nakamura & Lipton, 2008). 
GSH depletion and massive oxidation were also seen in Parkinson’s disease (Danielson 
& Andersen, 2008). Some observations suggest that progression of Prion disease is also 
related to ER redox state. Conversion of the soluble prion proteins into insoluble form is 
the key event in developing the disease. Reduced environment in the ER facilitates the 
production of insoluble prion proteins, thus increases the risk of developing Prion disease 
(Capellari et al, 1999; Tuzi et al, 2008).  
1.2.4.3 Dysregulation of ER calcium diseases status 
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               ER homeostasis is critical for cell survival. Abnormal cytosolic calcium caused 
by disturbance of calcium channels, calcium transporters, calcium binding proteins or 
calcium channels can induce disease manifestations. 
               In the case of T1D, β cells are destroyed by NO overproduction. NO depletes 
ER calcium by down-regulating SERCA2b production through inhibition of Sp1 
transcription factor (Pierre Pirot, Alessandra K Cardozo, 2008; Cardozo et al, 2005). NO 
can also form peroxynitrite in the presence of superoxide, which inhibits SERCA and 
activates RyR channels (Grover et al, 2003; Xu, 1998). Moreover, cytokines in T1D can 
up-regulate BH3-only proteins, thus leading to ER stress and calcium depletion (Gurzov 
et al, 2009). Additional evidence showing the importance of calcium homeostasis in T1D 
is that an IP3R3 polymorphism is associated with the disease (Roach et al, 2006). 
               T2D is also associated with dysregulated calcium homeostasis. Thapsigargin 
treatment depletes calcium in the ER and can cause insulin resistance (Ozcan et al, 2004). 
It has been shown that high glucose and free fatty acid treatment can cause ER calcium 
depletion as well as activate UPR pathways in pancreatic β cells (Eizirik et al, 2008). 
One possible mechanism for the ER calcium depletion is through a decreased level or 
activity of SERCA (Evans-Molina et al, 2009; Cunha et al, 2008). In a genetic form of 
diabetes—Wolfram syndrome, a defect in maintenance of ER calcium occurs and triggers 
UPR pathway leading to apoptosis (Hara et al, 2014).  
               Calcium disruption also takes place in the case of neuronal disorders. Brain 
ischemia induces ER calcium depletion into the cytosol (Verkhratsky, 2005). Increased 
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cytosolic calcium enhances NO synthesis, which can inhibit SERCA activity (Moncada 
& Erusalimsky, 2002; Doutheil et al, 2000). Neural ischemia can also activate RyR 
activity by induction of NO, reactive oxygen species and calpain proteolysis (Bull et al, 
2008; Rardon et al, 1990). Finally, there is strong evidence showing that in a genetic 
form of early onset Alzheimer’s disease, the presenilins have a crucial role in modulating 
intracellular calcium signaling (Sepulveda-Falla et al, 2014; Bezprozvanny, 2013). ER 
calcium stores are overfilled as a consequence of presenilin mutations. This alteration in 
calcium homeostasis is a driving force for PS-1 and PS-2 Alzheimer’s disease 
development. 
1.3 Calpain 
               Calpains are calcium dependent cysteine proteases. They form heterodimers 
composed of a large catalytic subunit and a small regulatory subunit. There are 14 
members of the human calpain family that have been identified as the catalytic subunit, 
together with two members of the regulatory subunit CAPNS1 and CAPNS2 (Suzuki et 
al, 2004; Vosler et al, 2008). Calpain 1 (also called u-calpain) and calpain 2 (also called 
m-calpain) are the best-characterized calpain family members; they share the same 
regulatory subunit (CAPNS1) but have distinct catalytic subunits CAPN1 and CAPN2. 
Activation of calpain requires translocation of the molecule from the cytosol to 
membranes. In the joint presence of high calcium and membrane phospholipids, calpain 
undergoes auto-hydrolysis to an active form. Activation of calpain must be tightly 
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regulated; dysregulation of calpain can cause excess cleavage or accumulation of 
substrate proteins leading to severe cell damage and pathological condition.  
               Calpains have been shown to participate in multiple activities including cell 
migration, cell cycle, neuron potentiation, necrosis, autophagy, and apoptosis. It was 
reported that calpain acted as a switch between autophagy and apoptosis by cleaving 
autophagy-related gene 5 (Atg5). (Yousefi et al, 2006) Cleaved Atg5 translocates to the 
mitochondria and triggers cytochrome c release and caspase activation, thus, inducing 
apoptosis. Hyper-activation of calpains is found in various diseases. In Alzheimer’s 
disease, studies showed significant increase of calpain activity in brains of Alzheimer’s 
disease patients. This may be due to enhanced intracellular calcium concentration 
induced by beta-amyloid or decreased calpastatin levels, which is an endogenous 
inhibitor of calpain (Saito et al, 1993; Ferreira & Bigio, 2011; Peterson & Goldman, 1986; 
Tsuji et al, 1998; Kelly et al, 2005; Kelly & Ferreira, 2006; Rao et al, 2008). In the case 
of type 2 diabetes, calpain 2 is hyper-activated, genetic screening for diabetes genes in 
Mexican-American and northern European populations revealed CAPN10 as a diabetes- 
susceptibility gene (Harris et al, 2006). Genetic variations of the CAPN10 gene are 
related to insulin resistance and elevated free fatty acids. Moreover, exposure of mouse 
islets to calpain inhibitor enhanced glucose stimulated insulin secretion (Sreenan et al, 
2001). Hyper-activation of calpains induces cleavage of downstream substrates including 
many cell structural proteins, ion channels and enzymes, thus, disrupting cellular 
structure and impairing cellular function (Figure 1.6). 
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CAPN2 has unique functions that cannot be substituted by CAPN1 (Dutt et al, 2006). 
CAPNS1 knockout mice were also embryonically lethal and died at day 11.5. They show 
defects in cardiovascular system and erythropoiesis (Arthur et al, 2000). In contrast, 
CAPNS1 heterozygous mice were phenotypically normal. Mouse embryonic fibroblasts 
(MEFs) lacking CAPNS1 totally diminished calpain 1 and calpain 2 activities revealing 
the importance of CAPNS1 in calpain activation and embryonic development (Tan et al, 
2006b). 
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CHAPTER II 
A CALCIUM-DEPENDENT PROTEASE AS A POTENTIAL 
THERAPEUTIC TARGET FOR WOLFRAM SYNDROME 
 
Summary 
               Wolfram syndrome is a genetic disorder characterized by diabetes and 
neurodegeneration and considered an endoplasmic reticulum (ER) disease. Despite the 
underlying importance of ER dysfunction in Wolfram syndrome and the identification of 
two causative genes, WFS1 and WFS2, a molecular mechanism linking the ER to death of 
neurons and β cells has not been elucidated. Here we show that calpain is a therapeutic 
target for Wolfram syndrome. Calpain 2 is negatively regulated by WFS2, and elevated 
activation of calpain 2 by WFS2-knockdown correlates with cell death. Calpain 
activation is also induced by high cytosolic calcium mediated by the loss of function of 
WFS1. Calpain hyper-activation is observed in the WFS1 knockout mouse as well as in 
neural progenitor cells derived from induced pluripotent stem (iPS) cells of Wolfram 
syndrome patients. A small-scale small-molecule screen targeting ER calcium 
homeostasis reveals that dantrolene can prevent cell death in neural progenitor cells 
derived from Wolfram syndrome iPS cells. Our results demonstrate that the pathway 
leading to calpain activation provides potential therapeutic targets for Wolfram syndrome 
and other ER diseases. 
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Introduction 
               The endoplasmic reticulum (ER) takes center stage for protein production, 
redox regulation, calcium homeostasis, and cell death (Ron & Walter, 2007; Tabas & 
Ron, 2011). Thus, it is little wonder that its genetic or acquired dysfunction can trigger a 
variety of common diseases, including neurodegenerative diseases, metabolic disorders, 
and inflammatory bowel disease (Hetz et al, 2013; Wang & Kaufman, 2012). Breakdown 
in ER function can also lead to genetic disorders such as Wolfram syndrome 
characterized by diabetes, optic atrophy, diabetes insipidus, and neurodegeneration 
(Fonseca et al, 2005, 2010; Barrett et al, 1995). It is challenging to determine the exact 
effects of ER dysfunction on the fate of affected cells in common diseases with polygenic 
and multifactorial etiologies. In contrast, we reasoned that it should be possible to define 
the role of ER dysfunction in mechanistically homogenous patient populations, especially 
in rare diseases with a genetic basis, such as Wolfram syndrome (Urano, 2014).  
               Wolfram syndrome (OMIM #222300) is a rare autosomal recessive disorder 
characterized by juvenile-onset diabetes mellitus and bilateral optic atrophy (Barrett et al, 
1995). Insulin dependent diabetes usually occurs as the initial manifestation during the 
first decade of life, while the diagnosis of Wolfram syndrome is invariably later with 
onset of the other features in the second and ensuing decades (Barrett et al, 1995; 
Marshall et al, 2013; Hershey et al, 2012). Two causative genes for this genetic disorder 
have been identified and named WFS1 and WFS2 (Inoue et al, 1998; Amr et al, 2007). It 
has been shown that multiple mutations in the WFS1 gene, as well as a specific mutation 
in the WFS2 gene, lead to β cell death and neurodegeneration through ER and 
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mitochondrial dysfunction (Fonseca et al, 2005, 2010; Chen et al, 2009b; Wiley et al, 
2013; Shang et al, 2014). WFS1 gene variants are also associated with a risk of type 2 
diabetes (Sandhu et al, 2007). Moreover, a specific WFS1 variant can cause autosomal 
dominant diabetes (Bonnycastle et al, 2013), raising the possibility that this rare disorder 
is relevant to common molecular mechanisms altered in diabetes and other human 
chronic diseases in which ER dysfunction is involved. 
               Despite the underlying importance of ER malfunction in Wolfram syndrome 
and the identification of WFS1 and WFS2 genes, a molecular mechanism linking the ER 
to death of neurons and β cells has not been elucidated. Here we show that the calpain 
protease provides a link between the ER and death of neurons and β cells in Wolfram 
syndrome.  
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Results 
               The causative gene for Wolfram syndrome, WFS1, encodes a ubiquitously 
expressed protein and has especially high expression in pancreatic β cells and neurons 
(Amr et al, 2007; Inoue et al, 1998; Fonseca et al, 2005). The localization of WFS2 is 
still controversial. To study the tissue and cellular localization of WFS2, we did 
immunoblot and immunofluorescence staining of various tissues and cells. We found that 
WFS2 is a ubiquitously expressed protein with high expression in the brain tissue (Figure 
2.1 A). WFS2 protein is not highly expressed in the pancreas, but mainly exists in islet 
cells (Figure 2.1 B). Similar to WFS1, WFS2 protein is also localized to the ER (Figure 
2.1 C). Mutations in the WFS1 or WFS2 have been shown to reduce neuronal and β cell 
mass in patients. But there was no animal model to study the disease with respect to cell 
death. Existing WFS1 knockout mice include the WFS1 β cell specific knockout mice 
and WFS1 whole body knockout mice. WFS1 β cell specific knockout mice do not have 
diabetes or β cell loss probably due to the fact that mice have stronger β cells than 
humans. Wfs1 whole body knockout do not show significant neural phenotypes. 
Therefore, we made WFS1 brain specific knockout mice by crossing WFS1 floxed/floxed 
mice with Nestin- CRE mice. We also imported WFS2 whole body knockout mice, 
which have been well studied in the aspect of aging and longevity but not Wolfram 
syndrome. After careful examination of the brain specific knockout mice along with the 
WFS2 whole body knockout mice, we determined tissue loss in a very specific  
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region of the brain in both Wolfram syndrome mouse models (Figure 2.2). By comparing 
the brain slices with brain atlas, the region was identified as substantial nigra, which is 
also the pathologically effected region in Parkinson’s disease. To confirm our observation, 
we stained the slides with tyrosine hydroxylase (TH), a dye for dopaminergic neurons, 
which are known to situate in the substantial nigra region of the brain, and saw perfect 
overlap of the tissue loss region and TH staining (Figure 2.3). This result implies that 
there is brain cell degeneration occurring.  
               To determine the cell death pathways emanating from the ER, we sought 
proteins that interact with Wolfram syndrome causative gene products. HEK293 cells 
were transfected with a GST-tagged WFS2 expression plasmid. The GST-WFS2 protein 
was purified along with associated proteins on a glutathione affinity resin. These proteins 
were separated by SDS-PAGE and visualized by Coomassie staining. Matrix-assisted 
laser desorption/ionization-time of flight (MALDI-TOF) mass spectroscopic analysis 
revealed 13 interacting proteins (Table 2.1), and one of the major WFS2 binding partners 
was CAPN2, the catalytic subunit of calpain 2, a member of the calcium dependent 
cysteine proteases family whose members mediate diverse biological functions including 
cell death (Goll et al, 2003; Tan et al, 2006a, 2006b) (Figure 2.4 A). Previous studies 
have shown that calpain 2 activation is regulated on the ER membrane and it plays a role 
in ER stress-induced apoptosis and β cell death (Tan et al, 2006a; Nakagawa & Yuan, 
2000; Cui et al, 2013; Huang et al, 2010), which prompted us to study the role of WFS2 
in calpain 2 activation.   
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                   Calpain 2 is a heterodimer consisting the CAPN2 catalytic subunit and the 
CAPNS1 (previously known as CAPN4) regulatory subunit. We first verified that WFS2 
interacts with calpain 2 by showing that endogenous calpain 2 subunits CAPN2 (Figure 
2.4 B) and CAPNS1 (Figure 2.4 C) each associated with GST-tagged WFS2 expressed in 
HEK293 cells.  Endogenous CAPN2 was also found to be co-immunoprecipated with N- 
or C-terminal FLAG-tagged WFS2 expressed in HEK293 cells (Figure 2.5 A and B 
respectively). To further confirm these findings, we performed a co-immunoprecipitation 
experiment in Neuro2a cells (a mouse neuroblastoma cell line) and INS-1 832/13 cells (a 
rat pancreatic β cell line) and found that endogenous WFS2 interacted with endogenous 
CAPN2 (Figure 2.4 D and E). WFS2 is known to be a transmembrane protein localized to 
the ER. We therefore explored the possibility that calpain 2 also localize to the ER. We 
transfected COS7 cells with pDsRed2-ER vector to visualize ER. Immunofluorescence 
staining of COS7 cells showed that endogenous calpain 2 was mainly localized to the 
cytosol, but also showed that a small portion co-localized with DsRed2-ER protein at the 
ER (Figure 2.4 F). Cell fractionation followed by immunoblot further confirmed this 
observation (Figure 2.5 C). Collectively, these results suggest that calpain 2 interacts with 
WFS2 at the cytosolic face of the ER. 
               Calpain hyper-activation has been shown to contribute to cell loss in various 
diseases (Goll et al, 2003), raising the possibility that calpain 2 might be involved in the 
regulation of cell death. To verify this issue, we overexpressed CAPN2, the catalytic 
subunit of calpain 2 and observed an increase of cleaved caspase-3 in HEK293 cells 
indicating that hyper-activation of calpain 2 induces cell death (Figure 2.4 G).  
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Table 2.1 GST-WFS2 interacting proteins 
 
 
 
 
 
 
 
 
 
     
Order on gel Gene Symbol Full name M.W. 
1 PRKDC DNA dependent protein kinase catalytic subunit 450 KDa 
2 COPA Coatomer Subunit alpha 140 KDa 
3 IPO7, 4, 9 Importin 7, 4, and 9 120 KDa 
4 XPO1, 2 Exportin 1, 2 110 KDa 
5 MMS19 MMS19 nucleotide excision repair 110 KDa 
6 CNX Calnexinp 67 Kda 
7 CAPN2 calpain-2 80KDa 
8 GRP78 GRP78 78 KDa 
9 TUBA TUBB Alpha and Beta Tubulin 50 Kda 
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               To determine whether WFS2 plays a role in cell survival, we suppressed WFS2 
expression in mouse neuronal NSC34 cells using siRNA and measured cell death under 
normal and ER stress conditions. WFS2 knockdown was associated with increased 
cleavage of caspase 3 in normal or ER stressed conditions (Figure 2.6 A and 2B). We 
subsequently evaluated calpain 2 activation by measuring the cleavage of alpha II 
spectrin, a substrate for calpain 2. RNAi-mediated knockdown of WFS2 induced calpain 
activation, especially under ER stress conditions (Figure 2.6 A).  
               In patients with Wolfram syndrome, destruction of β cells leads to juvenile-
onset diabetes (Barrett & Bundey, 1997). This prompted us to examine whether WFS2 
was also involved in pancreatic β cell death. As was seen in neuronal cells, knockdown of 
WFS2 in rodent β cell lines INS1 832/13 (Figure 2.6 C) and MIN6 cells (Figure 2.8) was 
also associated with increased caspase-3 cleavage under both normal and ER stress 
conditions. The association of WFS2 with calpain 2 and their involvement in cell 
viability suggested that calpain 2 activation might be the cause of cell death in WFS2-
deficient cells. To further explore the relationship between WFS2 and calpain 2, we 
expressed WFS2 together with the calpain 2 catalytic subunit CAPN2 and measured 
apoptosis. Ectopic expression of WFS2 significantly suppressed calpain 2-associated 
apoptosis under normal and ER stress conditions (Figure 2.7 A, lane 4 and lane 8, and 
Figure 2.7 B). Next, we tested whether CAPN2 mediates cell death induced by WFS2 
deficiency. When CAPN2 was silenced in WFS2-deficient cells, apoptosis was partially 
suppressed compared with untreated WFS2-deficient cells (Figure 2.7 C). Taken together,  
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Figure 2.8 WFS2 deficiency induces apoptosis in MIN6 cells. MIN6 cells were transfected 
with control scramble siRNA or siRNA directed against WFS2, and then treated with 0.5 µM 
thapsigargin (TG) for 6 h or untreated (UT). Expression levels of cleaved caspase 3, WFS2 and 
actin were measured by immunoblotting. (left panel) Quantification of cleaved caspase 3 is 
indicated in right panel (n=3, *P<0.05). 
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these results suggest that WFS2 is a negative regulator of calpain 2 pro-apoptotic 
functions.  
               To further confirm that loss of function of WFS2 leads to cell death mediated by 
calpain 2, we tested if calpeptin, a calpain inhibitor, could prevent cell death in WFS2 
deficient cells. In agreement with previous observations, calpeptin treatment prevented 
WFS2-knockdown-mediated cell death in neuronal (Figure 2.9 A and B) and β cell lines 
(Figure 2.9 C, and 2.11 A). Collectively, these results indicate that WFS2 is a suppressor 
of calpain 2-mediated cell death. 
               CAPN2 is the catalytic subunit of calpain 2. CAPN2 forms a heterodimer with 
the regulatory subunit, CAPNS1, which is required for protease activity and stability. We 
explored the role of WFS2 in CAPN2 and CAPNS1 protein stability. Ectopic expression 
or RNAi-mediated knockdown of WFS2 did not correlate with changes in the steady-
state expression of CAPN2 (Figure 2.11 B). By contrast, overexpression of WFS2 
significantly reduced CAPNS1 protein expression (Figure 2.10 A) and transient 
suppression of WFS2 slightly increased CAPNS1 protein expression (Figure 2.10 A). 
These data suggest that WFS2 might be involved in CAPNS1 protein turnover. Which is 
supported by the data showing GST-tagged WFS2 expressed in HEK293 cells associated 
with endogenous CAPNS1 (Figure 2.4 C). To investigate whether WFS2 regulates 
CAPNS1 stability through the ubiquitin-proteasome pathway, we treated HEK293 cells 
ectopically expressing WFS2 with a proteasome inhibitor, MG132, and then measured 
CAPNS1 protein level. MG132 treatment stabilized CAPNS1 protein in cells ectopically  
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Figure 2.11 Calpeptin inhibits WFS2 knockdown induced apoptosis. (A) MIN6 cells were 
transfected with scramble siRNA and WFS2 siRNA. Thirty-six h after transfection, cells were 
treated with or without 100 µM calpeptin for 12 h. Cleaved caspase 3, WFS2 and actin levels 
were monitored by immunoblotting. (B) CAPN2, WFS2 and actin levels were assessed by 
immunoblotting in HEK293 cells transfected with scramble siRNA (siCON), WFS2 siRNA 
(siWFS2) (left), empty expression plasmid (Mock), or WFS2 expression plasmid (right). 
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expressing WFS2 (Figure 2.10 B). Furthermore, we performed cycloheximide chase 
experiments using HEK293 cells ectopically expressing WFS2 and quantified CAPNS1 
protein level at different time points. Ectopic expression of WFS2 significantly decreased 
CAPNS1 protein levels at different time points. Ectopic expression of WFS2 was 
associated with significantly accelerated CAPNS1 protein loss, indicating that WFS2 
contributes to post-translational regulation of CAPNS1 (Figure 2.10 C). To further assess 
whether WFS2 is involved in the ubiquitination of CAPNS1, we measured the levels of 
CAPNS1 ubiquitination in cells ectopically expressing WFS2 and observed that CAPNS1 
ubiquitination level was increased by ectopic expression of WFS2 (Figure 2.10 D).  
               To further investigate the role of WFS2 in calpain 2 regulation, we collected 
brain lysates from WFS2 knockout mice and measured levels of cleaved spectrin, a well-
characterized substate for calpain (Liu et al, 2006a). Notably, protein expression levels of 
cleaved spectrin as well as CAPNS1 were significantly increased in WFS2 knockout 
mice compared to control mice (Figure 2.10 E). Collectively, these results indicate that 
WFS2 inhibits calpain 2 activation by regulating CAPNS1 degradation mediated by the 
ubiquitin-proteasome system. 
               Calpain 2 is a calcium-dependent protease. WFS1, the other causative gene for 
Wolfram syndrome, has been shown to be involved in calcium homeostasis (Takei et al, 
2006; Hara et al, 2014), suggesting that the loss of function of WFS1 may also cause 
calpain activation. To evaluate this possibility, we measured calpain activation levels in 
brain tissues from WFS1 brain specific knockout and control mice. We observed 
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significant increase of spectrin cleavage product, reflecting higher calpain activation 
levels in WFS1 knockout mice as compared to control mice (Figure 2.12 A). The 
suppression levels of WFS1 in different parts of the brain were shown in Figure 2.12 B. 
To further confirm that calpain is activated by the loss of WFS1, we looked for other 
calpain substrates in brain tissues from WFS1 knockout mice by a proteomics approach. 
Two-dimensional fluorescence difference gel electrophoresis experiment identified 12 
proteins differentially expressed between cerebellums of WFS1 knockout mice and those 
of control mice (Figure 2.13 A and B). Among these, myelin basic protein (MBP) is a 
known substrate for calpain in the brain (Liu et al, 2006b). We measured myelin basic 
protein levels in brain lysates from WFS1 knockout and control mice. Indeed, the 
cleavage and degradation of myelin basic protein was increased in WFS1 knockout mice 
as compared to control mice (Figure 2.13 C).  
               Next, we looked for evidence of increased calpain activity in Wolfram 
syndrome patient cells. We created neural progenitor cells derived from induced 
pluripotent stem cells (iPSCs) of Wolfram syndrome patients with mutations in WFS1. 
Fibroblasts from four unaffected controls and five patients with Wolfram syndrome were 
transduced with four reprogramming genes (Sox2, Oct4, c-Myc, and Klf4) (Takahashi & 
Yamanaka, 2006) (Table 2.2). We produced at least 10 clones from each control- and 
Wolfram-iPSCs. All control- and Wolfram-iPSCs, exhibited characteristic human 
embryonic stem cell morphology, expressed pluripotency markers including ALP, 
NANOG, SOX2, SSEA4, TRA-1-81, and had a normal karyotype (Figure 2.14 A-F). To  
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Table 2.2 Information on genotypes and phenotypes of Wolfram syndrome and control 
subjects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
iPSC line Source Clinical Diagnosis WFS1 mutation Sex Age at biopsy  Age at onset of DM  Age at onset of OA    Deafness DI 
 
Wolf-2010-5 Washington University Wolfram Clinic WFS H313Y F 15 3.8 12 1.7 NA 
Wolf-2010-9 Washington University Wolfram Clinic WFS A126T; W613X M 16 10.8 11 NA 14 
Wolf-2010-11 Washington University Wolfram Clinic WFS A126T; W613X M 10 7.5 6 8 10 
Wolf-2010-13 Washington University Wolfram Clinic WFS L200fs286Stop; E752Stop F 7 4.8 5.2 6 7.5 
GM01610 Corriell Research Institute WFS W648X; G695V F 11 NA NA NA NA 
BJ CRL-2522 ATCC Control NA M Newborn NA NA NA NA 
Wolf-2010-5-MO Washington University Wolfram Clinic Control None identified F 41 NA NA No No 
Wolf-2010-9 MO Washington University Wolfram Clinic Control NA F 33 NA NA No No 
Wolf-2012-13-FA Washington University Wolfram Clinic Control NA M 42 NA NA No No 
 
WFS, Wolfram syndrome; DM, diabetes mellitus; OA, optic atrophy; DI, diabetes insipidus 

50 
create neural progenitor cells, we first formed neural aggregates from iPSCs. Neural 
aggregates were harvested at day 5, re-plated onto new plates to give rise to colonies 
containing neural rosette structures. At day 12, neural rosette clusters were collected, re-
plated, and used as neural progenitor cells. In order to examine the differentiation 
potential of the neural progenitor cells, we tried to differentiate the neural progenitor cells 
into mature neurons. The differentiated neurons could be stained with TUJ1 antibody, 
indicating they are mature neurons. Interestingly, the control lines seem to differentiate 
more efficiently and form a better neural network then the Wolfram syndrome patient 
line. But this needs to be further investigated with more neural progenitor cell lines to 
draw any conclusions. Consistent with the data of WFS1 and WFS2 knockout mice, we 
observed that spectrin cleavage was increased in neural progenitor cells derived from 
Wolfram-iPSCs as compared to ones from control iPSCs, which indicates increased 
calpain activity (Figure 2.14 G).  
               Because calpain is known to be activated by high calcium, we explored the 
possibility that cytoplasmic calcium may be increased in patient cells by staining neural 
progenitor cells derived from control- and Wolfram-iPSCs with Fura-2, a fluorescent 
calcium indicator allowing accurate measurements of cytoplasmic calcium concentrations. 
Figure 2.14 H (left panel) shows that cytoplasmic calcium levels were higher in 
Wolfram-iPSCs derived cells than in control cells. This was confirmed by staining these 
cells with another fluorescent calcium indicator, Fluo-4 (Figure 2.14 H, right panel). 
Collectively, these results indicate that loss of function of WFS1 increases cytoplasmic 
calcium levels, leading to calpain activation. Next, we wanted to know whether there  
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Control
Patient
Figure 2.15 Differentiation and electron microscope scan of control and Wolfram syndrome 
patient neural progenitor cells (NPCs). (A) Differentiation of control (upper panels) and 
Wolfram syndrome patient (lower panels) NPCs. Neural progenitor cells were maintained in 
neural maturation media for 14 days. Then the cells were fixed and stained for mature neurons. 
Staining with anti-TUJ1 antibody is shown in red and DAPI staining of the neuron are shown in 
blue. (B) Electron microscopy scanning of control (upper panels) and patient (lower panels) 
NPCs. 
 
A
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were any visible damages in the organelles of the patient cells due to high calcium. We 
did electron microscope scanning of the neural progenitor cells from patients and control 
individuals, but did not detect any obvious damage in the organelles, which implies that 
the effect of increased cytosolic calcium is not acute. (Figure 2.15) This is consistent with 
the chronic pathological development history of Wolfram syndrome patients.  
               The results shown above demonstrate that the pathway leading to calpain 
activation provides potential therapeutic targets for Wolfram syndrome. To test this 
concept, we elected to focus on modulating cytosolic calcium and performed a small-
scale screen to identify chemical compounds that could prevent INS-1 cell death 
mediated by calcium dysregulation caused by thapsigargin, a known inhibitor for ER 
calcium ATPase. Among 73 well-characterized chemical compounds that we tested 
(Table 2.3), 8 chemical compounds could significantly suppress thapsigargin-mediated 
cell death. These were PARP inhibitor, dantrolene, NS398, pioglitazone, calpain inhibitor 
III, docosahexaenoic acid (DHA), rapamycin, and GLP-1 (Figure 2.16 A). GLP-1, 
pioglitazone, and rapamycin are FDA-approved drugs, and have been shown to confer 
protection against ER stress-mediated cell death (Liu et al, 2006a; Yusta et al, 2006; 
Akiyama et al, 2009; Bachar-Wikstrom et al, 2013). Dantrolene is another FDA-
approved drug clinically utilized for muscle spasticity and malignant hyperthermia 
(Michael & Dykes, 1975). It is of especially interesting because it had been shown to 
modulate ER and cytosolic calcium. Previous studies have shown that dantrolene is an 
inhibitor for the ER-localized ryanodine receptors and suppresses leakage of calcium  
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 Table 2.3 Chemical compounds used for a screen targeting ER calcium homeostasis. 
 
Drugs Treatment conc.
1 Nicotinamide(Vitamin B3) 10µM 
2 Valproic acid 10µM 
3 Sodium tauroursodeoxycholate(TUDCA) 10µM 
4 (-)-Riboflavin(Vitamin B2,Vitamin G) 10µM 
5 Thiamine hydrochloride(Vitamin B1 hydrochloride) 10µM 
6 Memantine hydrochloride 10µM 
7 (+-)-a-Lipoic acid 10µM 
8 Kynurenic acid 10µM 
9 Folic acid 10µM 
10 Idebenone 10µM 
11 Acetovanillone(Apocynin) 10µM 
12 Aspirin 10µM 
13 Pyridoxine hydrochloride 10µM 
14 Dextromethorphan hydrobromide 10µM 
15 2.3-Pyridinedicarboxylic acid(DPA) 10µM 
16 R-(-)-Deprenyl hydrochloride(Selegiline hydrochloride) 10µM 
17 NS-398 10µM 
18 4-Aminobenzoic acid(PABA,Vitamin Bx, Vitamin H1) 10µM 
19 Biotin 10µM 
20 D-Pantothenic acid hemicalcium salt(Vitamin B5) 10µM 
21 Chondroitin sulfate A sodium salt from bovine tracha(Glycosaminoglycans) 10µg/ml 
22 Ebselen 10µM 
23 PPBP maleate(4-PPBP maleate) 10µM 
24 Minocycline hydrochloride 10µM 
25 Pravastatin sodium salt hydrate 10µM 
26 N-tert-Butyl-alpha-phenylnitrine(PBN) 10µM 
27 Curcumin 10µM 
28 TRO19622(Olesoxime) 10µM 
29 Pyridoxamine dihydrochloride 10µM 
30 Pyridoxal hydrochloride 10µM 
31 Fibroblast Growth factor-Basic human 100ng/ml 
32 Bryostatin1 100nM 
33 Brain derived neurotrophic factor human 100ng/ml 
34 SRP4988(PEDF) 100ng/ml 
35 Erythropoietin 0.1UN/ml 
36 Clioquinol 10µM 
37 Kenpaullone 10µM 
38 PARP inhibitor iii,DPQ 10µM 
39 Glial Cell Line-derived Neurotrophic Factor human 100ng/ml 
40 Ciliary Neurotrophic Factor, human 100ng/ml 
41 Nitric Oxide Synthase, Neuronal Inhibitor 1(nNOS inhibitor) 10µM 
42 Riluzole 10µM 
43 Creatine 10µM 
44 Anisomycin from streptomyces griseolus 10µM 
45 NE 100 hydrochloride 10µM 
46 Phenytoin 10µM 
47 CsA 300nM 
48 FK506 300nM 
49 Rapamycin 10µM 
50 Docosahexaenoic acid 10µM 
51 GLP-1 50nM 
52 Diazoxide 300µM 
53 Glibenclamide 100µM 
54 2-APB (2-Aminoethoxydiphenyl borate) 200nM 
55 IL1RA 100ng/ml 
56 Retinol 10µM 
57 GW5015-16 10µM 
58 GW9508 10µM 
59 Etomoxir 20µM 
60 Verapamil 20µM 
61 Metformin 44uM 
62 AICAR 10µM 
63 pioglitazone 10µM 
64 Troglitazone 10µM 
65 N-Acetyl D-Shingosine 10µM 
66 Dihydroceramide C2 10µM 
67 Fumonisin B1 10µM 
68 Ros inhibitor 100µM 
69 SNAP 1mM 
70 Dantrolene 10µM 
71 Bcl XLBH4 human 1µM 
72 Calp. Inhibitor iii 1µM 
73 salburinal 25µM 
T bl  S3  Ch i l d  d f    i  h  ER l i  h i  
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from ER to cytosol (Wei & Perry, 2002; Luciani et al, 2009). We thus hypothesized that 
dantrolene can confer protection against calcium dysregulation induced cell death in 
Wolfram syndrome, and performed a series of experiments to investigate this possibility. 
We first examined if dantrolene could decrease cytoplasmic calcium levels in WT cells. 
As expected, dantrolene treatment decreased cytosolic calcium levels in INS-1 832/13 
and NSC34 cells (Figure 2.18 A and B). We next asked if dantrolene could restore 
cytosolic calcium levels in WFS1-deficient cells. RNAi-mediated WFS1 knockdown 
increased cytosolic calcium levels relative to control cells, and dantrolene treatment could 
restore cytosolic calcium levels in WFS1-knockdown INS-1 832/13 cells (Figure 2.16 B, 
left panel) as well as WFS1-knockdown NSC34 cells (Figure 2.16 B, right panel).  Next, 
to determine whether dantrolene confers protection in WFS1 deficient cells, we treated 
WFS1 silenced INS-1 832/13 cells with dantrolene and observed suppression in apoptosis 
(Figure 2.16 C) and calpain activity (Figure 2.17 A). Dantrolene treatment also prevented 
calpain activation and cell death in WFS1-knockdown NSC34 cells (Figure 2.17 B). To 
verify these observations in patient cells, we pretreated neural progenitor cells derived 
from iPS cells of a Wolfram syndrome patient and an unaffected parent with dantrolene, 
and then challenged these cells with thapisgargin. Thapsigargin-induced cell death was 
increased in neural progenitor cells derived from the Wolfram syndrome patient as 
compared to those derived from the unaffected parent, and dantrolene could prevent cell 
death in the patient neural progenitor cells (Figure 2.17 C). 
               In addition, we also treated tissue specific WFS1 knockout mice with dantrolene 
and saw a protective effect. In brain-specific knockout mice, dantrolene could suppress 
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calpain hyper-activation (Figure 2.17 D), while in islet-specific knockout mice, 
dantrolene treated mice show slightly increased insulin content in islets and some 
improvement in glucose intolerance which was not significant due to the fact that the 
mice only developed mild glucose intolerance before the treatment, which give us a small 
dynamic range to work with (Figure 2.20 A-C). Collectively, these results argue that 
dantrolene could prevent cell death in Wolfram syndrome by suppressing calpain 
activation.  
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Figure 2.18 Reduction of cytosolic calcium levels with dantrolene treatment. INS-1 832/13 
(A) and NSC34 (B) cells were pretreated with or without 10 µM dantrolene for 24 h. Cytoplasmic 
calcium levels were measured by Fura-2 calcium indicator over a period of time. Thapsigargin 
was added at 0 min time point (n=6).  
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Discussion 
               Growing evidence indicates that ER dysfunction triggers a range of human 
chronic diseases, including diabetes, atherosclerosis, inflammatory bowel disease, and 
neurodegenerative diseases (Hetz et al, 2013; Wang & Kaufman, 2012; Hotamisligil, 
2010; Ozcan & Tabas, 2012). However, currently there is no effective therapy targeting 
the ER for such diseases due to the lack of clear understanding of the ER’s contribution 
to the pathogenesis of such diseases. Although Wolfram syndrome is a rare disease and is 
currently neglected from mainstay drug discovery efforts, the homogeneity of the patient 
population and disease mechanism has enabled us to identify a potential target, a 
calcium-dependent protease, calpain. Our results provide new insights into how the 
pathways leading to calpain activation cause β cell death and neurodegeneration, which 
are schematically summarized in Figure 2.10 H. 
               There are two causative genes for Wolfram syndrome, WFS1 and WFS2. The 
functions of WFS1 have been extensively studied in pancreatic β cells. It has been shown 
that WFS1 deficient pancreatic β cells have high baseline ER stress levels and impaired 
insulin synthesis and secretion. Thus, WFS1-deficient β cells are susceptible to ER stress 
and cell death (Fonseca et al, 2005, 2010; Akiyama et al, 2009; Riggs et al, 2005; 
Ishihara et al, 2004; Zatyka et al, 2008). The functions of WFS2 are still not clear. There 
are evidences showing that impairment of WFS2 function can cause neural atrophy, 
muscular atrophy, mitochondrial dysfunction and accelerated aging in mice (Chen et al, 
2009b). WFS2 has also been shown to be involved in autophagy (Chang et al, 2010). 
However, although patients with two genetic types of Wolfram syndrome suffer from the 
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same disease manifestations, it was not clear if a common molecular pathway was altered 
in these patients. Our study has demonstrated for the first time that calpain hyper-
activation is the common molecular pathway altered in patients with Wolfram syndrome. 
The mechanisms of calpain hyper-activation are different in the two genetic types of 
Wolfram syndrome. WFS1 mutations cause calpain activation by increasing cytosolic 
calcium levels due to the dysfunction of ER calcium pump, whereas WFS2 mutations 
lead to calpain activation mainly due to impaired calpain inhibition. 
               Previously, Wolfram syndrome studies focused on pancreatic β cell function 
(Fonseca et al, 2005; Ishihara et al, 2004; Riggs et al, 2005). However, patients also 
suffer from neuronal manifestations. MRI scans of Wolfram syndrome patients showed 
atrophy in brain tissue implying neurodegeneration in patients (Barrett & Bundey, 1997; 
Hershey et al, 2012). In a mouse model of Wolfram syndrome, both WFS1 brain specific 
knockout mice and WFS2 whole body knockout mice showed sponging in the substantial 
nigra region of the midbrain. This sponging feature was previously seen in prion disease 
models, indicating loss of brain tissues. The sponging in Wolfram syndrome differs from 
prion disease in that it is restricted in a certain region while in prion disease, sponging 
occurs ubiquitously in the brain. Another difference we noticed is that the sponge holes in 
Wolfram syndrome seems larger then that of Prion’s disease. The next step we should 
take in Wolfram syndrome study is to try to understand the function of substantial nigra, 
what specific cell types are there and which ones are affected. Substantial nigra is a 
structure located in the midbrain that functions in reward and movement. It appears in a 
darker color due to high population of dopaminergic neurons in the area. Previous studies 
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have show that a neurodegenerative disease, Parkinson’s disease, patients experience loss 
of dopaminergic neurons in the substantial nigra region. The cause of death in 
dopaminergic neurons in Parkinson’s disease is unknown. One theory is accumulation of 
misfolded proteins activates programmed cell death in these cells. Another theory is that 
dopaminergic neurons in Parkinson’s patients contain less calbindin protein, leading to 
excess free calcium in the cytosol, which is toxic for cells. Interestingly, in Wolfram 
syndrome animal and cellular models, we also see induction of the UPR and high 
cytosolic calcium. This may hint that there are some common mechanisms between 
Parkinson’s disease and Wolfram syndrome.  
               In order to investigate the mechanisms of neurodegeneration in Wolfram 
syndrome human cells, we established Wolfram syndrome iPSC-derived neural 
progenitor lines and confirmed the observations found in rodent cells and animal models 
of Wolfram syndrome, which is higher basal UPR levels and higher cytosolic calcium 
levels in Wolfram syndrome samples. Yet, further differentiation of the neural progenitor 
cells into specific types of neurons such as dopaminergic neurons should be carried out in 
the future to dissect out the cell types damaged in Wolfram syndrome. This is crucial for 
more thorough study of the disease and future drug treatments. 
               Calpain activation has been found to be associated with type 2 diabetes and 
various neuronal diseases including Alzheimers, traumatic brain injury and cerebral 
ischemia, suggesting that activation of calpains is crucial for cellular health (Cui et al, 
2013). In our small-scale drug screening, we discovered that calpain inhibitor III could 
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confer protection against thapsigargin mediated cell death (Figure 6A). Our data also 
demonstrates that short-term calpeptin treatment was beneficial for cell with impaired 
WFS2 function. These results suggest that targeting calpain could be a novel therapeutic 
strategy for Wolfram syndrome. However, calpain is also an essential molecule for cell 
survival. Regulation of calpain activation level could be beneficial or toxic, thus we 
should carefully monitor calpain activity when treating patients with Wolfram syndrome 
(Dutt et al, 2006). 
               Calpain activation is tightly regulated by cytosolic calcium levels. In other 
syndromes that increase cytosolic calcium level in pancreatic β cells, patients experience 
a transient or permanent period of hyperinsulinaemic hypoglycemia. This can be partially 
restored by an inhibitor for ATP-sensitive potassium (KATP) channels or a calcium 
channel antagonist that prevents an increase in cytosolic calcium levels (Shah et al, 2014; 
Arya et al, 2014). Although patients with Wolfram syndrome do not experience a period 
of hyperinsulinaemic hypoglycemia, small molecule compounds capable of altering 
cellular calcium levels may hold promise for treating patients with Wolfram syndrome. 
Treatment of WFS1-knockdown cells with dantrolene and ryanodine could prevent cell 
death mediated by WFS1 knockdown. Dantrolene is a muscle relaxant drug prescribed 
for multiple sclerosis, cerebral palsy or malignant hyperthermia (Krause et al, 2004). 
Dantrolene inhibits the ryanodine receptors and reduces calcium leakage from the ER to 
cytosol, lowering cytosolic calcium level. First, we explored the effect of dantolene in 
vitro with neuronal and pancreatic β cell lines lacking WFS1, and found it to be 
protective. To further confirm the efficacy of dantrolene in vivo, we also treated WFS1 
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brain specific and WFS1 islet specific knockout mice with dantrolene for 4 weeks 
continuously. WFS1 brain specific knockout mice showed significant improvement in 
cleaved spectrin levels. While WFS1 islet specific knockout mice also showed some 
improvement in glucose intolerance, even though WFS1 islet specific knockout mice did 
not show significant impairment of islet function in the first place. This is probably due to 
the fact that mice have more robust β cells than humans. Dantrolene is widely used to 
treat muscle spasticity; it has also been studied in neurodegenerative diseases and 
proposed to be protective, but it has not been carefully studied in islets. This is the first 
time to show that it may be able to defend against diabetes related phenotypes in animal 
models. The protective effect of dantrolene treatment on WFS1 deficient cells and 
animals suggests that dysregulated cellular calcium homeostasis plays a role in the 
disease progression of Wolfram syndrome. In addition, it has been shown that stabilizing 
ER calcium channel function can prevent the progression of neurodegeneration in a 
mouse model of Alzheimer's disease (Chakroborty et al, 2012). Therefore, modulating 
calcium levels may be an effective way to treat Wolfram syndrome and even other ER 
diseases. 
               Dantrolene treatment did not block cell death mediated by WFS2 knockdown, 
suggesting that WFS2 does not directly affect the ER calcium homeostasis (Figure 2.19 B 
and C).   RNAi-mediated WFS1 knockdown in HEK293 cells significantly reduced the 
activation levels of sarco/endoplasmic reticulum calcium transport ATPase (SERCA), 
indicating that WFS1 may play a role in the modulation of SERCA activation and ER 
calcium levels (Figure 2.21 A and B). It has been shown that WFS1 interacts with the 
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Na+/K+ATPase β1 subunit and the expression of WFS1 parallels that of Na+/K+ ATPase 
β1 subunit in a variety of settings, suggesting that WFS1 may function as an ion channel 
or regulator of existing channels (Zatyka et al, 2008). Further studies on this topic would 
be necessary to completely understand the etiology of Wolfram syndrome. 
               Our present study reveals that dantrolene can prevent ER stress-mediated cell 
death in human and rodent cell models as well as mouse models of Wolfram syndrome. 
Thus, dantrolene and other drugs that can regulate ER calcium homeostasis could be used 
to delay the progression of Wolfram syndrome and other diseases associated with ER 
dysfunction, including type 1 and type 2 diabetes.  
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Materials and Methods 
Reagents 
               Thapsigargin, tunicamycin, calpeptin, dantrolene, ryanodine and cycloheximide 
were obtained from SIGMA (St. Louis, MO). RPMI-1640 and DMEM were from 
Invitrogen (Carlsbad, CA). Neural induction media, neural proliferation media were from 
Stemcell technologies (Vancouver, B.C., CA).  MitoProbe DilC1(5) mitochondrial 
membrane potential assay kit, Annexin V Alexa Flour488 conjugate, Fluo-4 and Fura-2 
calcium indicators were obtained from Invitrogen (Carlsbad, CA). Caspase-glo 3/7 
protease assay kit and calpain-glo protease assay kit was purchased from Promega 
(Madison, WI). Mito Stress test kit was from Seahorse Bioscience (North Billerica, MA) 
Anti-WFS2 antibody, and anti-WFS1 antibody were purchased from Proteintech 
(Chicago, IL), anti-Caspase 3, anti-CAPN2 antibodies were obtained from Cell Signaling 
Technology (Danvers, MA), anti-CAPNS1 and anti-alpha II spectrin antibody were 
obtained from Millipore (Billerica, MA). Anti-actin antibody was purchased from 
SIGMA (St. Louis, MO). Anti-Myelin basic protein antibody was from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti- Calpain 2 antibody, which detects both CAPN2 
and CAPNS1, was raised in rabbits against bacterially expressed rat calpain 2. 
Plasmids and siRNA 
               pCMV-SPORT6-WFS2 expression plasmid was purchased from Open 
Biosystems. pDsRed2-ER vector was purchased from Clonetech (Mountain View, CA). 
FLAG tagged WFS2 plasmids were constructed by inserting FLAG sequences into the N- 
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and C-termini of the expression plasmid. GST-WFS2 plasmid was generated by inserting 
WFS2 sequence into pEBG mammalian expression plasmid.   A CAPN2 expression 
plasmid was generated in pLenti-CMV-puro plasmid provided by E. Campeau (Campeau 
et al., 2009). Lipofectamine2000 (Invitrogen, Carlsbad, CA) was used to transfect small 
interfering RNA (siRNA) directed against WFS2 and CAPN2 into cells. siRNAs were 
designed and synthesized at QIAGEN (Valencia, CA) as follows: mouse WFS2 
CAACAGAAGGAUAGCUUG, human WFS2 CGAAAGUAGUGAAUGAAA, human 
CAPN2 CCGAGGAGGUUGAAAGUA. Rat WFS1 GUUUGACCGCUACAAGUUU. 
Cells were incubated in media overnight after siRNA transfection, and then additional 
treatments were performed, including ER stress induction. 
Cell culture 
               Neuro-2a, NSC34, HEK293, MEFs and COS7 cells were cultured in DMEM 
containing 10% FBS, penicillin 100 U/ml and streptomycin 100 U/ml. MIN6 cells were 
grown in DMEM containing 15% FBS penicillin 100 U/ml and streptomycin 100 U/ml. 
INS-1 832/13 cells were cultured in RPMI containing 10% FBS, penicillin 100 U/ml, 
streptomycin 100 U/ml, 2-mercaptoethanol 3 µM, sodium pyruvate 1mM. Human 
fibroblasts were grown in FBM fibroblast basal medium supplemented with FGM-2 
SingleQuots from Lonza (Basel, Switzerland), iPSCs were cultured in a feeder cell free 
system with mTeSR1 media from Stemcell Technologies (Vancouver, British Columbia, 
CA). Neural progenitor cells were generated in STEMdiff Neural Induction Media and 
maintained in STEMdiff Neural Progenitor Medium from Stemcell Technologies. 
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iPS cells and neural progenitor cells generation 
               To generate iPS cells, we obtained fibroblasts from non-affected controls and 
patients with Wolfram syndrome. Integration-free iPS cells were generated via Sendai 
viral delivery of the four reprogramming factors, Oct4, Sox2, Klf4, and c-Myc using Life 
Technologies’ Cytotune reagents and protocol. All WFS- and control-iPSCs showed 
silencing of the four transgenes, exhibited characteristic human embryonic stem cell 
morphology, expressed pluripotency markers including ALP, NANOG, SOX2, SSEA4, 
TRA-1-81, and had a normal karyotype. To generate neural progenitor cells, iPSCs were 
counted and plated ~50,000 cells per well in a 96-well plate to form uniform embryoid 
bodies. After 5 days, embryoid bodies were suspended in neural induction media and 
replated as adherent cultures. Fresh media were applied every day for 7 days.  Neural 
rosettes formed in these cultures were selected and plated. Plated rosettes were fed with 
STEMdiff Neural Induction Media every day for 4-7 days to obtain neural progenitor 
cells. 
Maintenance of neural progenitor cells 
               Neural progenitor cells were plated on poly-ornithine (Sigma) and laminin 
(Sigma) double-coated plates (ready made poly-ornithine 37 oC, 2 h + laminin 10 µg/ml 
37 oC, 2h). Plating density was ~1.0x105 per cm2. Cells were maintained in STEMdiff 
Neural Progenitor medium from Stemcell Technologies with daily medium changes until 
100% confluent. Once the cells were confluent and ready for splitting, accutase was 
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applied to detach the cells. For freezing the cells, Bambanker cell freezing medium 
(Wako Chemicals, Osaka, JP) was used. 
Differentiation of neural progenitor cells into mature neurons 
               Neural progenitor cells were cultured in maturation medium (neural basal 
medium A supplied with N2 supplement, B27 supplement, cAMP 10 µM, Noggin 500 
ng/ml, retinoic acid 0.1 µM, SHH 50 ng/ml, BDNF 10 ng/ml, GDNF 10 ng/ml, IGF1 10 
ng/ml) with daily medium changes for 2-3 weeks to obtain mature motor/ dopaminergic 
neurons. 
MALDI-TOF mass spectrometry 
               HEK293 cells were transfected with GST-WFS2 plasmid and empty GST 
plasmid. Cell lysates were collected and immunoprecipitated with glutathione beads in 
lysis buffer (150 mM NaCl, 0.5% TritonX-100, 50 mM HEPES, 1 mM EDTA, 1 mM 
DTT, pH7.5). The precipitated proteins from both samples were resolved by SDS-PAGE 
and stained with Coomassie blue staining (Bio-Rad, Hercules, CA). The distinct bands 
that only appear in GST-WFS2 lane but not GST lane were analyzed by MALDI-TOF 
tandem mass spectrometry on a Shimadzu Axima TOF2 mass spectrometry at University 
of Massachusetts Medical School Proteomics and Mass Spectrometry Facility. 
Immunostaining 
               Cells were fixed in 4% paraformaldehyde for 30 min at room temperature and 
then permeabilized with 0.1% Triton X-100 for 2 min. The fixed cells were washed twice 
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with PBS/Tween 0.1%, blocked with Image-It FX signal enhancer (Invitrogen, Carlsbad, 
CA) for 1 hour and incubated in primary antibody overnight at 4 °C. The next day, cells 
were washed three times in PBS/Tween 0.1% and incubated with secondary antibody for 
1 h at room temperature, then cells were washed with PBS/Tween 0.1% for another three 
times and PBS twice and mounted with a Prolong Slowfade Reagents (Life Technologies, 
Carlsbad, CA) and sealed. Images were obtained with a Zeiss LSM 5 PASCAL confocal 
microscope with LSM Image software. 
Hematoxylin and eosin (H&E) staining 
               Mouse brain specimen was fixed in 10% formalin for 2 days, embedded in 
paraffin, and processed for histopathologic examination. Paraffin-embedded serial 
sections were stained with hematoxylin and eosin (H&E).  
Intraperitoneal glucose tolerance test (IPGTT) 
               Four weeks after dantrolene injection, WFS1 islet specific knockout mice (n=5 
each group) were subjected to IPGTT. After 16 h fasting, glucose (2 g/kg) was injected 
intraperitoneally. Blood was drawn from end of the tail at time points 0, 30, 60, 90 and 
120 min to measure blood glucose using a glucometer 
Islet isolation 
               Pancreatic islets were isolated by pancreatic duct injection of 500 U/ml of 
collagenase solution followed by digestion at 37 °C for 40 minutes with mild shaking. 
Islets were then washed several times with Hank’s balanced salt solution (HBSS), 
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separated from acinar cells on a discontinuous Ficoll 400 gradient, viewed under a 
dissecting microscope and hand-selected.  
Glucose stimulated insulin secretion (GSIS) 
               Thirty islets of similar size per mouse were picked after overnight culture and 
transferred into a 1.5ml tube. After incubation in 1ml of 3.3 mM glucose Kreb’s (KRB) 
buffer (137 mM NaCl, 4.7 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 2.5 mM CaCl2, 
25 mM NaHCO3, pH 7.4) for 1hr at 37°C, islets were then incubated in 1ml of 16.7mM 
glucose in KRB for another 2hr. Secreted insulin was quantified using supernatant of 
sample with insulin ELISA kit from Invitron (Monmouth, UK). 
Insulin content 
               Thirty islets of similar size were picked per mice after overnight culture and 
lysed with T-PER tissue lysis buffer. Extracted protein was diluted and analyzed for 
insulin content by insulin ELISA kit from Invitron. 
FACS analyses  
               For flow cytometry analyses, neural progenitor cells or NSC34 cells were plated 
in 24-well plates. After staining with the relevant fluorescence dye, cells were washed 
and resuspended in PBS. Flow cytometry analyses were performed with LSRII (Becton 
Dickson, Franklin Lakes, NJ) at the FACS core facility of Washington University School 
of Medicine. The results were analyzed by FlowJo ver.7.6.3.  
Quantitative Real-Time PCR 
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               Total RNA was extracted by RNeasy kits (Qiagen, Venlo, Limburg, NL). 
Reverse transcriptase PCR was performed using High Capacity Reverse Transcription Kit 
(Applied Biosystems, Carlsbad, CA) and quantitative PCR was demonstrated with 
Applied Biosystems ViiA7 using SYBR green dye.  
2-D fluorescence difference gel electrophoresis 
               Proteins were extracted from cerebellums from WFS1 knockout mice and 
control mice. Equal amount of protein extract from paired samples were labeled by 
CyDye DIGE fluors, and the spectrally resolvable dyes enabled simultaneous co-
separation and analysis of samples on a single multiplexed gel. These paired samples 
were simultaneously separated on a single 2D gel, using isoelectric focusing (IEF) in the 
first dimension and SDS polyacrylamide gel electrophoresis (SDS-PAGE) in the second 
dimension. After electrophoresis, the gel was scanned using a Typhoon image scanner. 
Each scan revealed one of the CyDye signals (Cy3 and Cy5). ImageQuant software was 
used to generate the image presentation data including the single and overlay images. The 
comparative analysis of all spots was done by the DeCyder analysis software. The protein 
expression ratios between WFS1 knockout and control mice were generated, and 
differentially expressed spots were analyzed by MALDI-TOF mass spectrometry. 
SERCA activity assay 
               The SERCA activity assay was performed as previously described in (Funai, 
Song et al. 2013). HEK293 cells were homogenized in hypotonic buffer, consisting of 10 
mM NaHCO3, 250 mM sucrose, 5 mM NaN3, and 0.1 mM PMSF. ER fraction was 
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isolated using differential centrifugation. 125 to 300 mg of ER protein fraction were 
added to the assay mixture [100 mM KCL, 30 mM imidazole-histidine (pH 6.8), 5 mM 
MgCl2, 5 mM ATP, 5 mM (COOK)2, 5 mM NaN3, and 50 µM CaCl2 (10 uCi/µmol[45Ca]; 
CaCl2 American Radiolabeled Chemicals)] heated to 37oC for 15 minutes. The reaction 
was stopped by the addition of 250 mM KCl and 1 mM LaCl3. The mix was then vacuum 
filtered through a 0.2 µm HT Tuffryn membrane (Sigma).  SERCA-dependent calcium 
transport was measured by comparing calcium transport with and without the presence of 
the 10 µM thapsigargin, a SERCA inhibitor. 
Human Subjects 
               Wolfram syndrome patients were recruited through the Washington University 
Wolfram Syndrome International Registry website 
(http://wolframsyndrome.dom.wustl.edu/medical-research/Wolfram-Syndrome-
Home.aspx). The clinic protocol was approved by the Washington University Human 
Research Protection Office and all subjects provided informed consent if adults and 
assent with consent by parents if minor children (IRB ID 201107067 and 201104010).  
Animal experiments 
               WFS1 brain specific knockout mice were generated by breeding the Nestin-Cre 
transgenic mice (Jackson laboratory, Bar Harbor, ME) with WFS1 floxed mice (41). 
WFS2 whole body knock out mice are purchased from MRC Harwell (Oxfordshire, UK). 
All animal experiments were performed according to procedures approved by the 
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Institutional Animal Care and Use Committee at the Washington University in Saint 
Louis School of Medicine (A-3381-01). 
Calcium levels 
               Calcium levels in cells were measured with an Inifinite M1000 plate reader 
(Tecan, Mannedorf, Switzerland). Neural progenitor cells or lymphocytes were plated in 
96 well plates at a density of 25,000 cells per well and stained with 4 µg/ml Fura-2 
(Invitrogen) dissolved in PBS for 30 min at 37 oC. 2.5 mM of probenecid (Invitrogen) 
was also added to the staining buffer to sustain the dye. Then the cells were washed with 
PBS supplemented with probenecid and incubated at room temperature for an additional 
15 min. Fluorescence was measured at excitation wavelength 510 nm and emission 
wavelength 340 nm and 380 nm. Ratio of 340 nm and 380 nm was calculated.  
               Calcium levels in cells were measured by flow cytometry. Neural progenitor 
cells were plated in 12 well plate at a density of 5x105 cells per well and stained with 4 
µg/ml Fluo-4 dye dissolved in probenecid (2.5 mM) supplemented PBS for 30 min at 37 
oC. Then cells were washed with probenecid containing PBS and incubated at room 
temperature for another 15 min. Fluorescence intensity of these cells was analyzed by 
flow cytometry. 
Statistical analysis 
               Two-tailed t-tests were used to compare the two treatments. P values below 0.05 
were considered significant. All values are shown as means ± S.D. if not stated. 
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CHAPTER III 
PROSPECTIVES 
 
Studying Wolfram syndrome is important for understanding diabetes and 
neurodegenerative diseases. 
               Globally as of 2013, an estimate of 381 million people had diabetes. This 
number is still increasing rapidly, especially in developing countries. By 2030, it is 
predicted that this number will double. In the United States, diabetes is the 7th leading 
cause of death. In 2012, an estimate of 29.1 million Americans (9.3% of the population) 
had diabetes and another 86 million adults were prediabetic. In 2013, diabetes cost $245 
billion in United States and at least $500 billion globally (Yang et al, 2013). 
               Today, 35.6 million people worldwide suffer from Alzheimer's disease; 10 
millions from Parkinson's; 2.5 million from multiple sclerosis (MS); 120,000 from 
amyotrophic lateral sclerosis (ALS), and over 350,000 from Huntington's disease. 
Because neurodegenerative diseases strike primarily later in life, the incidence is 
expected to soar as the population ages.  As our average life span increase, 30 years from 
now, more than 12 million Americans will suffer from neurodegenerative diseases. 
               The challenge in understanding diabetes and neurodegenerative diseases is that 
they are complex disorders caused by multiple risk factors including genetics factors, 
lifestyles and environmental factors. Researchers have identified at least 20 chromosomal 
regions associated with type 1 diabetes, and more than a dozen genes linked to type 2 
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diabetes (Pociot & McDermott, 2002; Rich et al, 2008). Studies done on multiple 
sclerosis, a type of neurodegenerative disorder, revealed more than 19 regions on the 
genome are related to the disease (Sawcer et al, 1996). In addition to the large number of 
genes contributing to diabetes and neurodegenerative disorders, environmental factors 
and lifestyles such as diet and exercise also play a role that cannot be ignored. 
Discovering a risk factor and estimating its contribution to a complex disease is difficult, 
due to the fact that the contribution of each factor may be subtle or cofounded by other 
factors. What’s more, the effect of environmental factors may obscure the impact of a 
single risk factor. 
               Studying a monogenetic disorder can provide insight into the contribution of a 
single gene in more complicated diseases. Although mutations are relatively rare, these 
genes are usually essential for health. Variants in monogenetic disorder genes have also 
been shown to be associates with common diseases (Brinkman et al, 2006). In the case of 
amyotrophic lateral sclerosis (ALS), there is a monogenetic form, which accounts for 2% 
of total ALS patients (Rosen, 1993). These patients have a gain of function mutation in 
the SOD1 gene. By studying this monogenetic form of ALS, scientists were able to 
determine that mutant SOD1 induced damage of mitochondria, protease, and protein 
folding machinery were mechanisms contributing to the disease (Wong et al, 1995; 
Tobisawa et al, 2003; Nishitoh et al, 2008; Steinacker et al, 2014). Further studies proved 
that these mechanisms were also present in general ALS population (Swerdlow et al, 
1998; Chattopadhyay & Valentine, 2009; Atkin et al, 2008; Ito et al, 2009). Thus, 
revealing the biological progression and molecular pathogenesis of monogenetic disorder 
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can contribute to discovery of novel therapeutic targets for both rare and common 
diseases. 
               Wolfram syndrome is an autosomal recessive monogenetic disorder 
characterized by juvenile-onset diabetes, optic atrophy and progressive 
neurodegeneration. Two causative genes for Wolfram syndrome have been identified—
Wolfram syndrome 1 (WFS1) and Wolfram syndrome 2 (WFS2).  Both prototypes of 
Wolfram syndrome are monogenetic disorders. WFS1 has also been shown to be a top 
risk factor in Type 2 diabetes. Understanding the disease mechanism for Wolfram 
syndrome may give us a clue of the pathogenesis of diabetes and neurodegenerative 
disorders. The goal of our study was to reveal the possible cause of cellular death in 
Wolfram syndrome and find a possible treatment. In this thesis, I showed that through 
calcium leakage or protein regulation, loss of WFS1 or WFS2 leads to hyperactivation of 
calpain, which latter induces apoptosis. This finding may shed light on mechanisms of 
more complex disorders that represent the same disease phenotypes. In the last part of 
chapter 2, I demonstrated that dantrolene might be a good mechanism-based drug for 
Wolfram syndrome. This may also apply to other diseases caused by disruption of 
calcium homeostasis. 
Potential treatments for Wolfram syndrome and other genetic diseases 
1. Genetic modification 
               For genetic diseases, especially monogenetic disease such as Wolfram 
syndrome, genetic medicine is a straightforward strategy. By transferring genetic 
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materials that are lacking in patients, we may be able to reverse the pathological 
phenotype. To date, genetic medicine approaches have been tested in clinic. The first 
attempt to cure human disease by gene transfer was in 1990, since then, 95 human trials 
have been carried out for gene transfer worldwide, all directed against monogenetic 
diseases (Blaese et al, 1995). These human trials proved that gene transfer could be 
applied in human patients to induce phenotypic modifications. But, gene transfer 
efficiency, host immune response, expression sufficiency, delivery specificity, possible 
mutagenesis are still challenges that we are facing. Further modification of the vectors 
and delivery methods are necessary before establishing it as a standard treatment for 
patients.  
2. Chaperones and drugs 
               Previous studies showed that Wolfram syndrome is an ER stress disease. Loss 
of the WFS1 gene leads to continuous activation of UPR component ATF6, which further 
induce CHOP expression resulting in cell death. Eliminating ER stress in Wolfram 
syndrome might be beneficial for patients. Extensive studies on ER stressed showed that 
chaperones, either endogenous chaperones or chemical chaperones, are effective in 
reducing ER stress levels. Chaperones are small molecules that can facilitate and stabilize 
the folding of proteins. Endogenous protein chaperones in human includes BIP, which is 
a component of the UPR. Overexpression of BIP has been shown to be protective for 
many ER stress diseases. Chemical chaperones are small compounds whose functions 
include non-specifically stabilizing misfolded proteins, preventing protein aggregation 
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and regulating the activity of endogenous chaperones. It has been shown that pretreating 
cells with chemical chaperones 4-phenyl butyric acid (PBA) or tauroursodeoxycholic 
acid (TUDCA) can protect against ER stress induced cell death. In a type 2 diabetic 
mouse model, the ob/ob mice, treatment with PBA and TUDCA can alleviate ER stress, 
improve glucose intolerance and insulin sensitivity. (Ozcan et al, 2006) Here, we tested 
the effect of chemical chaperones in Wolfram syndrome patient fibroblasts, and observed 
stabilization of the mutant WFS1 protein with TUDCA and curcumin treatment. Since 
many Wolfram syndrome patients have point mutations in WFS1 gene encoding unstable 
but functional proteins, by stabilizing these proteins, we might be able to mitigate the 
pathological phenotypes in these patients. 
               In this work, we also did small-scale screening of drugs that are protective 
against calcium dyshomeostasis induced death. Out of the 8 positive hits we discovered, 
dantrolene was the most interesting one. Not only is it a FDA approved drug, but also 
because it is a known calcium regulator, which makes it a mechanism-based drug. 
Dantrolene has been proscribed as a muscle relaxant, and also studied in 
neurodegenerative diseases (Krause et al, 2004; Li et al, 2005; Huafeng Wei 1996), but 
it’s application on other tissues and disorders have not been fully investigated. In this 
work, we propose that dantrolene could be a candidate drug for Wolfram syndrome and 
even other complex disorders such as diabetes, which also show dysregulation of cellular 
calcium. 
3. Induced pluripotent stem cells transplantation 
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               Stem cell therapy is another option for Wolfram syndrome. This year, the first 
clinical trial on human using induced pluripotent stem cells (iPSCs) was performed in 
Japan (Kamao et al, 2014). It was used to treat age-related macular degeneration. If the 
trial turns out successful, it would be good news for numerous patients. iPSCs 
transplantation has its advantages. First of all, it is autologous transplantation, thus 
inducing no immune response in patients. Secondly, the source of iPSCs is easy to obtain, 
it can come from any cell types, skin fibroblast being the most popular. Moreover, we can 
genetically modify cells before transplanting back into the patients. Lastly, unlike drugs, 
iPSCs could be regulated by in vivo signals and they respond to environmental factors, 
precisely producing the right amount of ingredients the body needs. Presently, insulin 
injection is widely used by T1D patients and some T2D patients to prevent diabetes 
complications. Besides being a painful and tedious process, injection of insulin needs to 
be carefully monitored, else, over-dosage may lead to hypoglycemia, another harmful 
symptom. A method that can concisely regulate the amount of insulin patients received is 
in urgent need (Borowiak & Melton, 2009). Recent publication showed the successful 
generation of functional pancreatic β cells from human pluripotent stem cells (Pagliuca et 
al, 2014). Transplantation of these cells into diabetic mice greatly ameliorated 
hyperglycemia and more importantly, they can secrete insulin into the serum in a glucose 
dependent manner. Hopefully in the near future, iPSCs differentiated β cells will be 
applied in clinical trials for diabetic patients. In the case of Wolfram syndrome, for 
patients who have milder symptoms and later onset, we can derive iPSCs into neurons 
and pancreatic β cells and transplant them back into the patients. For Wolfram syndrome 
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patients with more severe symptoms, we need to correct the mutant WFS1 allele in the 
genome before transferring the cells back to the patients. Otherwise, loss of the newly 
transferred neurons and β cells might occur again in their lifetime. Though much progress 
has been made in iPSCs studies, challenges still exist. The current challenge for iPSCs 
treatment is the differentiation step. Methods for direct differentiation of iPSCs into 
specific cell types have been developed over the years, but efficiency and quality of the 
process still remains to be improved in the future. 
ER homeostasis is a critical checkpoint for diseases 
               When we try to understand the cellular mechanism of a disease, the first few 
aspects that we tend to examine are apoptosis, mitochondrial respiration, and basic 
cellular functions such as proliferation defect or migration abnormality. Here we show 
that ER homeostasis is another critical checkpoint for diseases. The ER is the major site 
of protein folding, protein modification, lipid metabolism and calcium level modulation. 
When the ER cannot fulfill all its functions properly due to genetics defects or 
environmental stimuli, the balance of ER homeostasis is disrupted, and cells become 
unhealthy. 
1. Tools developed to identify dysregulated ER homeostasis 
               Currently, the classical method for monitoring ER homeostasis is by 
determining the levels of UPR markers such as BiP, CHOP and spliced XBP1. While this 
remains a convincing approach, accumulation of unfolded proteins only reflects one 
aspect of ER homeostasis. ER homeostasis also includes the retention of ER calcium, 
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modulation of ER redox state, regulation of lipid metabolism, etc. Precise and feasible 
tools that can provide real time monitoring of the ER status are in urgent need. Previously, 
scientists developed an ER resident redox-sensitive GFP in yeast to dynamically measure 
ER redox state (Merksamer et al, 2008). The redox-sensitive GFP experiences 
conformational change under distinct pH conditions and exhibits altered emission signal 
intensities at excitation 400 and 490 nm. By calculating the fluorescence signal ratio from 
these two excitation wavelengths, we can estimate the ER redox status. Later this 
technology was also introduced into the mammalian system (Kanekura et al, 2013). 
Similar tools can also be developed to monitor ER calcium and ER lipid synthesis. One 
method is to establish ER calcium probes that emit distinct signals when free or bounded 
to calcium to visualize calcium level changes. To understand the dynamics of calcium 
ions, we can also use calcium radioisotope to chase calcium uptake and release in the ER. 
ER is also an important organelle for fatty acid synthesis and cholesterol metabolism. 
Scientists have already developed probes for live cell imaging of lipids, if co-expressed 
with an ER marker such as pDsRed ER, it would be possible to analyze ER lipid content 
and trafficking with a live imaging tool.  
 
2. Modulating ER homeostasis can facilitate disease prevention and treatment 
               In many cases, ER homeostasis disruption is the first sign of disease symptom, 
and if left untreated, an array of anti-survival pathways will be activated and cells will 
undergo massive cell death. However, if treated properly to regain normal ER function, 
these cells could be rescued. What’s more, we can mimic ER dysregulation status from 
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various diseases, or even different stages of the same disease, and screen for drugs to 
prevent or treat these diseases at different stages. 
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